Royal Bank of Canada
ACAD icon

Royal Bank of Canada’s Acadia Pharmaceuticals ACAD Stock Holding History

Royal Bank of Canada’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-50,000
Closed -$1.4M – 6338
2016
Q1 		$1.4M Buy
+50,000
New +$1.09M ﹤0.01% 2759

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Royal Bank of Canada's ACAD Position: Q1 2026 in Review

Royal Bank of Canada reduced its Acadia Pharmaceuticals (ACAD) stake by 23% in Q1 2026, selling an estimated $1.62M and leaving 223,155 shares worth $4.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2421.

Royal Bank of Canada first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $19.9M in Q2 2016. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Royal Bank of Canada held 223,155 shares of Acadia Pharmaceuticals worth $4.97M as of Q1 2026.
  • Royal Bank of Canada sold 67,699 Acadia Pharmaceuticals shares in Q1 2026, an estimated $1.62M.
  • Acadia Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2421 holding.
  • Royal Bank of Canada first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Acadia Pharmaceuticals position peaked at $19.9M in Q2 2016.
  • 342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.